Beneath the headlines, two distinct threads are converging toward the same point. The first is regulatory: psilocybin remains Schedule I, rescheduling requires a formal FDA approval triggering DEA administrative process, and no NDA has been filed — but the scaffolding for that filing is now substantially more complete. At 78% confidence, the swarm sees an NDA submission within 18 months as the most probable next milestone, with today's RCT cluster functioning as pivotal supportive evidence. The second thread is scientific: the ibogaine plasticity finding is not a clinical result — it is a basic neuroscience result of the kind that reorganizes funding priorities. Critical period reopening in adult neural tissue via a single compound is the type of discovery that generates NIH R01 cycles, redirects graduate training, and seeds the next decade of mechanistic work. These two threads — the clinical and the basic — are rarely this synchronized. What is forming is a mutual reinforcement: clinical trials provide political legitimacy, basic science provides mechanistic depth, and together they make the field harder to dismiss and harder to slow.
The human beings closest to today's signals are the veterans who have already traveled to clinics in Mexico and Canada because no legal domestic pathway exists — and the patients with treatment-resistant depression who have exhausted every approved option and are now watching, with a particular kind of attention, as RCT after RCT returns results that look like what they have been told is impossible. For veterans, the ibogaine plasticity finding means something specific: it suggests that what they experienced in underground or international settings may not be symptom suppression but genuine neural reorganization, which changes both the ethical stakes and the clinical argument. For the depression cohort, the accumulating trial data means the waiting is measurable now — it has a timeline, a filing window, a regulatory logic. That is not hope as abstraction. That is hope with a mechanism.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
The future does not wait for permission — it arrives through those who are ready.
88%
Psilocybin stays illegal until at least end of 2027
Psilocybin will almost certainly remain a Schedule I drug (illegal with no accepted medical use) through 2027 because no company has yet filed an NDA (the FDA application required to approve a new drug). Even after an NDA is approved, the DEA (the federal agency that controls drug legality) needs 12-24+ months to formally change psilocybin's legal status. Since the clock hasn't even started, rescheduling by 2028 is unlikely.
→ Psilocybin will remain illegal through 2027 because no company has filed for FDA approval yet, and the approval-to-legal-status process takes years.
Resolves: 2027-12-31 · USA
REGULATORY
the precise call ▾
Psilocybin will remain Schedule I through end of 2027, as no NDA has been filed and DEA rescheduling requires completion of a formal administrative process that FDA approval would trigger but publication volume cannot accelerate.. The regulatory pathway is structural: FDA NDA approval is a prerequisite for DEA rescheduling review; neither COMPASS nor any competitor has filed an NDA as of May 2026; the administrative law process (notice-and-comment rulemaking or expedited review) takes 12-24+ months even after NDA approval; th
62%
Psilocybin NDA filed for depression treatment by late 2027
COMPASS Pathways or a competitor will likely submit an NDA (formal approval application) to the FDA by November 2027 for psilocybin as a treatment for severe depression that doesn't respond to other drugs. They have completed Phase 3 trials (the final human testing stage) and have publicly said they're preparing the application. This doesn't mean psilocybin will be approved or legal yet—just that the formal FDA review process will begin.
→ A major company will likely file for FDA approval of psilocybin for depression by late 2027, starting the formal review process.
Resolves: 2027-11-30 · USA
REGULATORY
the precise call ▾
A psilocybin NDA for treatment-resistant MDD will be filed with the FDA by COMPASS Pathways or a direct competitor by November 2027, citing recent RCT data as supportive evidence alongside existing Phase 3 results.. COMPASS has completed Phase 3 trials and has publicly signaled NDA preparation. The 18-month window (to November 2027) is realistic for NDA compilation and submission given existing data packages. However, competitor filings are uncertain, and COMPASS's own timeline has slipped before. The cocaine u
78%
Major news will hype psilocybin addiction cure, then quietly correct
When researchers announce that psilocybin helped people quit cocaine, major news outlets will publish headlines saying psychedelics 'cure addiction'—even though the actual finding is much narrower (psilocybin reduced cravings in one study). Within 2-4 weeks, scientists and careful reporters will publish corrections and pushback. This cycle confuses the public and makes Congress skeptical of psychedelic funding.
→ News outlets will exaggerate psilocybin's addiction benefits, corrections will follow, and Congress will become more skeptical.
Resolves: 2026-06-20 · USA
CULTURE
the precise call ▾
At least one major mainstream US news outlet will publish a headline characterizing the cocaine use disorder psilocybin RCT results as evidence that 'psychedelics cure addiction' within 30 days of publication, followed by a correction cycle that complicates congressional messaging.. The pattern is well-established across MDMA, ketamine, and prior psilocybin-depression coverage: mechanistically precise findings (e.g., extinction enhancement, reduced cue reactivity) are compressed into triumphalist framings by generalist reporters optimizing for engagement. The correction or crit
38%
Ibogaine brain plasticity finding sparks three NIH grants
A recent discovery that ibogaine (a psychedelic) can reopen brain plasticity windows in adults is so important that the NIH (US medical research agency) will likely fund at least three R01 grants (major research awards) specifically to study how this works. This is aggressive because NIH typically funds only 1 in 5 grant proposals, and the finding needs time to get recognized and peer-reviewed. Within 18 months of May 2026 (by late 2027) is the deadline.
→ The ibogaine plasticity finding is landmark, but landing three major research grants within 18 months is a difficult bet.
Resolves: 2027-11-20 · USA
RESEARCH
the precise call ▾
The ibogaine juvenile plasticity finding will generate at least 3 NIH R01 grant awards (not merely applications) specifically targeting critical period plasticity mechanisms within 18 months of May 2026.. Critical period reopening in adult cortex via a single compound is a genuinely field-reorganizing result if replicated. However, the prediction as originally stated conflates grant cycles initiated with grants funded: R01 cycles run 6-9 months from application to award, and study sections must first